TWI861099B - 包含抗rsv抗體之組合物及劑量方案 - Google Patents

包含抗rsv抗體之組合物及劑量方案 Download PDF

Info

Publication number
TWI861099B
TWI861099B TW109114519A TW109114519A TWI861099B TW I861099 B TWI861099 B TW I861099B TW 109114519 A TW109114519 A TW 109114519A TW 109114519 A TW109114519 A TW 109114519A TW I861099 B TWI861099 B TW I861099B
Authority
TW
Taiwan
Prior art keywords
rsv
seq
antigen
binding fragment
monoclonal antibody
Prior art date
Application number
TW109114519A
Other languages
English (en)
Chinese (zh)
Other versions
TW202106333A (zh
Inventor
阿尼斯 艾哈邁德 韓
維德萊恩 皮爾
Original Assignee
英商梅迪繆思有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司 filed Critical 英商梅迪繆思有限公司
Publication of TW202106333A publication Critical patent/TW202106333A/zh
Application granted granted Critical
Publication of TWI861099B publication Critical patent/TWI861099B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
TW109114519A 2019-04-30 2020-04-30 包含抗rsv抗體之組合物及劑量方案 TWI861099B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30

Publications (2)

Publication Number Publication Date
TW202106333A TW202106333A (zh) 2021-02-16
TWI861099B true TWI861099B (zh) 2024-11-11

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109114519A TWI861099B (zh) 2019-04-30 2020-04-30 包含抗rsv抗體之組合物及劑量方案

Country Status (15)

Country Link
US (3) US12024553B2 (https=)
EP (1) EP3962940A1 (https=)
JP (2) JP2022531205A (https=)
KR (1) KR20220002427A (https=)
CN (1) CN113825767A (https=)
AU (1) AU2020265676A1 (https=)
BR (1) BR112021020846A2 (https=)
CA (1) CA3138180A1 (https=)
CO (1) CO2021014370A2 (https=)
EA (1) EA202192776A1 (https=)
IL (1) IL287443A (https=)
MX (1) MX2021013248A (https=)
SG (1) SG11202111748TA (https=)
TW (1) TWI861099B (https=)
WO (1) WO2020223435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2023039584A2 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201840334A (zh) * 2017-03-01 2018-11-16 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201840334A (zh) * 2017-03-01 2018-11-16 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Zhu, Qing et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science translational medicine vol. 9 American Association for the Advancement of Science 2017 eaaj1928 *

Also Published As

Publication number Publication date
EA202192776A1 (ru) 2022-01-19
JP2025072444A (ja) 2025-05-09
US20220204593A1 (en) 2022-06-30
JP2022531205A (ja) 2022-07-06
CN113825767A (zh) 2021-12-21
WO2020223435A1 (en) 2020-11-05
TW202106333A (zh) 2021-02-16
CA3138180A1 (en) 2020-11-05
AU2020265676A1 (en) 2021-11-18
SG11202111748TA (en) 2021-11-29
BR112021020846A2 (pt) 2022-01-18
US20240417447A1 (en) 2024-12-19
US20200347120A1 (en) 2020-11-05
CO2021014370A2 (es) 2021-10-29
EP3962940A1 (en) 2022-03-09
KR20220002427A (ko) 2022-01-06
MX2021013248A (es) 2022-01-24
IL287443A (en) 2021-12-01
US12024553B2 (en) 2024-07-02

Similar Documents

Publication Publication Date Title
Johnson et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
US20100239585A1 (en) Antibodies Against Mammalian Metapneumovirus
CA2521826A1 (en) Recombinant il-9 antibodies and uses thereof
IL263819A (en) Preparations and methods for treating immunodeficiency
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
TW201908334A (zh) 生物製藥組成物及相關方法
JP2023554456A (ja) 呼吸器合胞体ウイルスに特異的に結合する分子
WO2020219719A1 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
JP2025537301A (ja) Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
AU2022361501B2 (en) Anti-sars-cov-2 antibodies and uses thereof i
EP4413122A1 (en) Anti-sars-cov-2 antibodies and uses thereof i
JP2025542128A (ja) メタニューモウイルス融合（ｆ）タンパク質に対する抗体及びその使用
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
RU2807524C2 (ru) Составы антител к rsv и способы их применения
US20250188153A1 (en) Hmpv antibodies and their use
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
JP2024535009A (ja) ニルセビマブによる呼吸器合胞体ウイルス下気道感染の予防
WO2022079001A2 (en) Sars-cov-2 antigens, diagnostic and therapeutic uses
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies
Zohar et al. Upper and Lower Respiratory Tract Correlates of Protection Against RSV Following Vaccination of Non-Human Primates